PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|December 28, 2015
Valeant Announces CEO on Medical Leave
Author(s)Pharmaceutical Technology Editors
Valeant announced its CEO, J. Michael Pearson, will be on medical leave of absence after being hospitalized for pneumonia.
Advertisement
On Dec. 28, 2015 Valeant Pharmaceuticals International, Inc., announced that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective immediately.
The company's board of directors has created an office of the chief executive officer (CEO), which will include Robert Chai-Onn, executive vice-president and general counsel, Ari Kellen, PhD, executive vice-president and company group chairman, and Robert Rosiello, executive vice-president and chief financial officer, to serve in an interim capacity.
In addition, the board of directors has created a committee to oversee and support the office of the CEO and will include Robert A. Ingram, lead independent director, G. Mason Morfit, president, ValueAct Capital, and Howard B. Schiller, former chief financial officer of Valeant.
Valeant confirmed last week that Pearson had recently been hospitalized and was being treated for a severe case of pneumonia.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
3
FDA's IND Pilot Puts CMC Review First
4
Successful Internal Audit Planning and Execution
5